Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Nursing Care of Patients Receiving Campath®

Karen Seeley
Elaine DeMeyer
CJON 2002, 6(3), 138-143 DOI: 10.1188/02.CJON.138-143

Monoclonal antibodies are focused therapies with unique in fusion-related complications. Campath® (alemtuzumab, Berlex Laboratories, Richmond, CA) is indicated for the treatment of refractory chronic lymphocytic leukemia and has a complicated administration schedule, severe infusion-related toxicity, and profound immunosuppressive capability. Ambulatory cancer care is challenging simply because of the complex nature of the disease. Management of complicated therapies, such as Campath, stretches resources and requires a coordinated effort by the healthcare team for successful patient outcomes.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or